EP0456640A4 - Genetically engineered endothelial cells and use thereof. - Google Patents

Genetically engineered endothelial cells and use thereof.

Info

Publication number
EP0456640A4
EP0456640A4 EP19900900691 EP90900691A EP0456640A4 EP 0456640 A4 EP0456640 A4 EP 0456640A4 EP 19900900691 EP19900900691 EP 19900900691 EP 90900691 A EP90900691 A EP 90900691A EP 0456640 A4 EP0456640 A4 EP 0456640A4
Authority
EP
European Patent Office
Prior art keywords
endothelial cells
genetically engineered
engineered endothelial
genetically
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19900900691
Other languages
German (de)
French (fr)
Other versions
EP0456640A1 (en
Inventor
W French Anderson
Scott M Freeman
James A Zweibel
Thompson J Anthony
Una S Ryan
Philip Kantoff
David Dichek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
University of Miami
Original Assignee
US Department of Health and Human Services
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, University of Miami filed Critical US Department of Health and Human Services
Publication of EP0456640A4 publication Critical patent/EP0456640A4/en
Publication of EP0456640A1 publication Critical patent/EP0456640A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
EP90900691A 1988-12-13 1989-12-08 Genetically engineered endothelial cells and use thereof Withdrawn EP0456640A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28358688A 1988-12-13 1988-12-13
US283586 1988-12-13

Publications (2)

Publication Number Publication Date
EP0456640A4 true EP0456640A4 (en) 1991-09-20
EP0456640A1 EP0456640A1 (en) 1991-11-21

Family

ID=23086736

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90900691A Withdrawn EP0456640A1 (en) 1988-12-13 1989-12-08 Genetically engineered endothelial cells and use thereof

Country Status (4)

Country Link
EP (1) EP0456640A1 (en)
JP (1) JPH04507041A (en)
CA (1) CA2005199A1 (en)
WO (1) WO1990006997A1 (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6001350A (en) * 1987-12-11 1999-12-14 Somatix Therapy Corp Genetic modification of endothelial cells
US6140111A (en) * 1987-12-11 2000-10-31 Whitehead Institute For Biomedical Research Retroviral gene therapy vectors and therapeutic methods based thereon
US6544771B1 (en) 1987-12-11 2003-04-08 Cell Genesys, Inc. Retroviral gene therapy vectors and therapeutic methods based thereon
EP0568537B1 (en) * 1990-10-31 1998-02-04 Somatix Therapy Corporation Genetic modification of endothelial cells
US5464450A (en) * 1991-10-04 1995-11-07 Scimed Lifesystems Inc. Biodegradable drug delivery vascular stent
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
PT101031B (en) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc PROCESS FOR THE SUPPLY OF PROTEINS BY GENETIC THERAPY
US6692737B1 (en) 1991-11-05 2004-02-17 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6054288A (en) * 1991-11-05 2000-04-25 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
FR2683725B1 (en) * 1991-11-15 1995-07-07 Pasteur Institut CELL COMPOSITION FOR THE TREATMENT OF HUMAN OR ANIMAL ORGANISMS.
US6348327B1 (en) 1991-12-06 2002-02-19 Genentech, Inc. Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6627615B1 (en) 1991-12-17 2003-09-30 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
US5756353A (en) * 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
WO1993012240A1 (en) 1991-12-17 1993-06-24 The Regents Of The University Of California Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr)
US5336615A (en) * 1992-01-06 1994-08-09 Yale University Genetically engineered endothelial cells exhibiting enhanced migration and plasminogen activator activity
AU3429993A (en) * 1992-01-10 1993-08-03 Georgetown University A method of administering genetically engineered endothelial cells to sites of angiogenesis for effecting genetic therapy
US6806084B1 (en) 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
EP0646178A1 (en) * 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US6531124B1 (en) 1992-07-10 2003-03-11 Transkaryotic Therapies, Inc. In vivo production and delivery of insulinotropin for gene therapy
US6670178B1 (en) 1992-07-10 2003-12-30 Transkaryotic Therapies, Inc. In Vivo production and delivery of insulinotropin for gene therapy
CA2149771A1 (en) 1992-11-18 1994-05-26 Jeffrey M. Leiden Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
US5645829A (en) * 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
IL113052A0 (en) 1994-03-23 1995-06-29 Rhone Poulenc Rorer Sa Recombinant viruses, their preparation and their use in gene therapy
WO1995025547A1 (en) * 1994-03-24 1995-09-28 University Of Washington Devices and methods for implanting transduced cells
WO1996006933A1 (en) * 1994-08-26 1996-03-07 Sandoz Ltd. Gene therapy for transplantation and inflammatory or thrombotic conditions
US5704910A (en) 1995-06-05 1998-01-06 Nephros Therapeutics, Inc. Implantable device and use therefor
CN1052915C (en) * 1995-11-27 2000-05-31 中国医学科学院生物医学工程研究所 Medical carrier of protein coat for carrying gene and its prodn. method
US6723531B2 (en) 1996-04-05 2004-04-20 The Salk Institute For Biological Studies Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
FR2758569B1 (en) * 1997-01-20 1999-04-02 Centre Nat Rech Scient BIOLOGICAL MATERIAL FOR THE TREATMENT OF A MAMMAL BY TRANSFERRING ANTIBODY GENE AND PHARMACEUTICAL COMPOSITION CONCERNING THE SAME
US6300488B1 (en) 1997-07-10 2001-10-09 The Salk Institute For Biological Studies Modified lepidopteran receptors and hybrid multifunctional proteins for use in transcription and regulation of transgene expression
US6206914B1 (en) * 1998-04-30 2001-03-27 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
US6333318B1 (en) 1998-05-14 2001-12-25 The Salk Institute For Biological Studies Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
EP1144594A1 (en) * 1998-11-24 2001-10-17 Regents Of The University Of Minnesota Transgenic circulating endothelial cells
US7504253B2 (en) 1999-06-11 2009-03-17 The Burnham Institute For Medical Research Nucleic acid encoding proteins involved in protein degradation, products and methods related thereof
CA2383093A1 (en) * 1999-09-23 2001-03-29 An-Go-Gen Inc. Cell-based gene therapy for the pulmonary system
US7057015B1 (en) 1999-10-20 2006-06-06 The Salk Institute For Biological Studies Hormone receptor functional dimers and methods of their use
AU2001231009A1 (en) 2000-01-21 2001-07-31 Beth Israel Deaconess Medical Center Use of pro-apoptotic factors in treatment of atherosclerosis
US6706688B2 (en) 2001-03-09 2004-03-16 Paula Sundstrom Methods for regulating bud-hypha transitions and cAMP levels by the adenylate cyclase-associated protein gene, CAP1
US7270975B2 (en) 2001-03-09 2007-09-18 Trustees Of Dartmouth College Methods for regulating bud-hypha transitions and cAMP levels in Candida albicans
EP1404713A4 (en) 2001-05-24 2004-09-22 Human Dna Technology Inc Novel keratinocyte growth factor-2 analogue in hair follicle
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
CA2524619A1 (en) 2005-11-22 2007-05-22 Ottawa Health Research Institute Novel stem cells, nucleotide sequences and proteins therefrom
WO2008097927A2 (en) 2007-02-06 2008-08-14 Tai June Yoo Treatment and prevention of neurodegenerative diseases using gene therapy
CA2728215A1 (en) 2008-06-18 2010-06-24 Innovative Biotherapies, Inc. Methods for enhanced propagation of cells
JP2014528715A (en) 2011-09-15 2014-10-30 ロサンゼルス バイオメディカル リサーチ インスティテュート アットハーバー− ユーシーエルエー メディカル センター Immunotherapy and diagnosis of mucormycosis using CotH
EP3003393A4 (en) 2013-06-04 2017-01-11 The Johns Hopkins University Tripartite cancer theranostic nucleic acid constructs
EP3004153B1 (en) 2013-06-04 2019-10-30 Virginia Commonwealth University Recombinant cancer therapeutic cytokine
US9701985B2 (en) 2013-06-04 2017-07-11 Virginia Commonwealth University mda-9/syntenin promoter to image and treat metastatic cancer cells
EP3004357A4 (en) 2013-06-04 2017-01-11 The Johns Hopkins University Peg-prom mediated surface expression of avidin/streptavidin
EP3003022B1 (en) 2013-06-04 2017-11-22 Virginia Commonwealth University Use of a truncated ccn1 promoter for cancer diagnostics, therapeutics and theranostics
EP3299460A1 (en) 2016-09-26 2018-03-28 Johann Wolfgang Goethe-Universität Frankfurt am Main Novel compounds and methods for modulating ubiquitination
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
US20210047425A1 (en) 2019-08-12 2021-02-18 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
TW202128775A (en) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 Pd-l1 inhibitor - tgfβ inhibitor bispecific drug moieties
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
WO2023057567A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Pd-l1 binding affimers
WO2023057946A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008450A1 (en) * 1987-05-01 1988-11-03 Birdwell Finlayson Gene therapy for metabolite disorders
WO1989002468A1 (en) * 1987-09-11 1989-03-23 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
WO1990015863A1 (en) * 1989-06-13 1990-12-27 The Board Of Directors Of The Leland Stanford Junior University Isolation growth and differentiation of human muscle cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008450A1 (en) * 1987-05-01 1988-11-03 Birdwell Finlayson Gene therapy for metabolite disorders
WO1989002468A1 (en) * 1987-09-11 1989-03-23 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
WO1990015863A1 (en) * 1989-06-13 1990-12-27 The Board Of Directors Of The Leland Stanford Junior University Isolation growth and differentiation of human muscle cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9006997A1 *

Also Published As

Publication number Publication date
CA2005199A1 (en) 1990-06-13
EP0456640A1 (en) 1991-11-21
WO1990006997A1 (en) 1990-06-28
JPH04507041A (en) 1992-12-10

Similar Documents

Publication Publication Date Title
EP0456640A4 (en) Genetically engineered endothelial cells and use thereof.
GB2221300B (en) Enzyme electrodes and improvements in the manufacture thereof
HK56395A (en) Stack method and circuitry.
AU3478193A (en) Genetically engineered endothelial cells
HUT43874A (en) Genes degredating halogenarylnitriles and cells comprising the genes
NO894489L (en) IMPROVEMENTS IN AND IN CONNECTION WITH PACKAGING.
IL87001A0 (en) Haloarylnitrile degrading gene,and cells containing the gene
JPS6460373A (en) Human cells and trioner, antibody and trasformer derived from said cells
GB8829198D0 (en) Improvements in structure materials
GB2201372B (en) Ostomy bags and materials.
GB2227329B (en) Load cell
EP0344110A3 (en) Substituted naphthacenes-5,12-diones and their use
GB2216337B (en) Solar cell and fabrication method thereof
NO894399D0 (en) OPTICALLY ACTIVE BENZOXASINES AND BENZOTIAZINES.
EP0344109A3 (en) Substituted naphthacene-5,12-diones and their use
AU3493689A (en) Tin-containing copolymers and their use
EP0348933A3 (en) Standard cell
GB8830363D0 (en) Improvements in load handling
GB8802464D0 (en) Cell
GB8817497D0 (en) Improvements in lgazing
EP0284426A3 (en) Polyethylene teraphthalate and uses thereof
GB8818210D0 (en) Acoustic emission load cell
NZ235781A (en) Cells expressing altered n alpha -acetyltransferase
GB2226728B (en) Improvements in amplifiers
AU5163390A (en) Tenascin-induced cell attachment and the tenascin receptor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19910515

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19940617

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19941228